Interferon-α and Bcr-Abl Antisense Oligodeoxynucleotides in Combination Enhance the Antileukemic Effect and the Adherence of CML Progenitors to Preformed Stroma

References

• Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr. on chromosome 22. Cell 1984; 36: 93–99
   PubMed Web of Science ®Google Scholar
• Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogeneous leukemia. Nature 1985; 315: 550–554
   PubMed Web of Science ®Google Scholar
• Gale R. P., Canaani E. An 8 Kb abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 1984; 81: 5648–5654
   PubMed Web of Science ®Google Scholar
• Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035–1040
   PubMed Web of Science ®Google Scholar
• Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguamera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 1991; 253: 562–565
   PubMed Web of Science ®Google Scholar
• de Fabritiis P., Amadori S., Calabretta B., Mandelli F. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant 1993; 12: 261–265
   PubMed Web of Science ®Google Scholar
• Luger S. M., Ratajczak M. Z., Stadtmauer E. A., Mangan P., Magee D., Silberstein L., Edelstein M., Nowell P., Gewirtz A. M. Autografting for chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotide purged bone marrow. Blood 1994; 84(suppl. 1), Abstr. 591
   Google Scholar
• de Fabritiis P., Petti M. C., Montefusco E., De Propris M. S., Sala R., Bellucci R., Mancini M., Lisci A., Bonetto F., Geiser T., Calabretta B., Mandelli F. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 9: 3156–3162
   Google Scholar
• Cashman J., Eaves A. C., Eaves C. J. Regulated proliferation of primitive hematopoieticprogenitors in long-term human marrow cultures. Blood 1985; 66: 1002–1005
   PubMed Web of Science ®Google Scholar
• Bathia R., Wayner E. A., McGlave P. B., Verfaillie M. C. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 Integrin receptor function. J. Clin. Invest. 1994; 94: 384–391
   PubMed Web of Science ®Google Scholar
• Bathia R., McGlave P. B., Verfaillie M. C. Treatment of marrow stroma with interferon-α restores normal β1 Integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. J. Clin. Invest. 1995; 96: 931–939
   PubMed Web of Science ®Google Scholar
• Bathia R., Verfaillie M. C. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 Integrin-mediated adhesion and proliferation inibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998; 91: 3414–3422
   PubMed Web of Science ®Google Scholar
• de Fabritiis P., Skorski T., De Propris M. S., Paggi M. G., Nieborowska-Skorska M., Lisci A., Buffolino S., Campbell K., Geiser T., Calabretta B. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukemia cells. Leukemia 1997; 1: 811–819
   Web of Science ®Google Scholar
• Pegoraro L., Matera L., Ritz J., Levis A., Palumbo A., Biagini G. Establishment of a Ph-positive human cell line (BV-173). J Natl Cancer Inst 1983; 70: 447–451
   PubMed Web of Science ®Google Scholar
• Bellucci R., De Propris M. S., Buccisano F., Lisci A., Leone G., Tabilio A., de Fabritiis P. Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. Bone Marrow Transplant 1999; 22: 1–8
   Web of Science ®Google Scholar
• Dowding C., Guo A.-P., Osterholz J., Sickowski M., Goldman J., Gordon M. Interferon α overrides deficient adhesion of chronic myelogenous leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499–505
   PubMed Web of Science ®Google Scholar
• Verfaillie C. M., McCarthy J. B., McGlave P. B. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteration in their adhesion to fibronectin. J. Exp. Med. 1991; 174: 693–703
   PubMed Web of Science ®Google Scholar
• Teixedo J., Hemler M. E., Greenberger J. S., Anklesaria P. Role of B1 and B2 integrins in the adhesion of human CD34+ stem cells to bone marrow stroma. J. Clin. Invest. 1992; 90: 358–367
   PubMed Web of Science ®Google Scholar
• Kirkland M. A., O'Brien S. G., McDonald C., Davidson R. J., Cross N. C. P., Goldman J. M. BCR-ABL anti-sense purging in chronic myeloid leukemia (letter). Lancet 1993; 342: 614
   PubMed Web of Science ®Google Scholar
• Smetsers T. F., van de Locht L. T., Pennings A. H., Wessels H. M., de Witte T. M., Mensink E. J. Phosphorothioate BCR_ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 1995; 9: 118–130
   PubMed Web of Science ®Google Scholar
• Mahon F. X., Ripoche J., Pigeonnier V., Jazwiec B., Pigneux A., Moreau J. F., Reiffers J. Inibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995; 23: 1606–1611
   PubMed Web of Science ®Google Scholar
• O'Brien S. G., Kirkland M. A., Melo J. V., Rao M. H., Davidson R. J., McDonald C., Goldman J. M. Anti-sense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 1994; 8: 2156–2162
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Barletta C., Malaguarnera L., Szczylik C., Chen S. T., Lange B., Calabretta B. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest. 1993; 92: 194–202
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Wlodarski P., Perrotti D., Hoser G., Kawiak J., Majewski M., Christensen L., Iozzo R. V., Calabretta B. Treatment of Philadelphia leukemia in severe combined immunodeficent mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst 1997; 89: 124–133
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Nicolaides N. C., Szczylik C., Iversen P. Cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1994; 31: 4504–4508
   Web of Science ®Google Scholar
• de Fabritiis P., Amadori S., Petti M. C., Mancini M., Montefusco E., Picardi A., Geiser T., Campbell K., Calabretta B., Mandelli F. In vitro purging with BCR-ABL anti-sense oligodeoxynucleotides does not prevent hematological reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662–664
   PubMed Web of Science ®Google Scholar